Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. (Q51532739)
Jump to navigation
Jump to search
scientific article published on 6 August 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. |
scientific article published on 6 August 2016 |
Statements
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib. (English)
Steffen Filskov Sorensen
Christina Demuth
Britta Weber
Boe Sandahl Sorensen
6 August 2016
77-84